TAK-117

Phase 1Small molecule

Takeda

TAK-117 is one of 59 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Hepatitis BActive, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Hepatitis BPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Vizimpro

Pfizer

Preclinical

4 6

Remeron

OOrganon and Co

Preclinical

1 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Completed· Takeda logo

Takeda·Phase 1·NCT01899053·101 enrolled

Advanced Cancer1 trial

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Completed· Takeda logo

Takeda·Phase 1·NCT01449370·125 enrolled

Gastric1 trial

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Completed· Takeda logo

Takeda·Phase 1·NCT02625259·54 enrolled

Non-Small Cell Lung Cancer1 trial

Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Terminated· Takeda logo

Takeda·Phase 1/2·NCT02393209·14 enrolled

Advanced Solid Tumors1 trial

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

Completed·—·Phase 1·NCT03154294·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TAK-117. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-117 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-117. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Takeda

TAK-117

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematologic Malignancies1 trial

Advanced Cancer1 trial

Gastric1 trial

Non-Small Cell Lung Cancer1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News